MedTrace Logo

Pr-conceptional Progesterone for Unexplained Recurrent Miscarriage

NCT01670929 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 700

Last updated 2016-04-05

No results posted yet for this study

Summary

In women with unexplained recurrent miscarriages, progesterone (400 mg pessaries, twice daily), started soon as possible at luteal phase and after a positive pregnancy test and continued to 28 weeks of gestation, compared to placebo, ).

Conditions

  • Abortion, Habitual

Interventions

DRUG

Progesterone

OTHER

Placebo

Sponsors & Collaborators

  • Woman's Health University Hospital, Egypt

    lead OTHER

Principal Investigators

  • Alaa M Ismail, M D · Faculity of medicine,Assiut university

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2015-05-31
Completion
2015-11-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01670929 on ClinicalTrials.gov